Depression is a common symptom among gastric cancer (GC) patients and serves as a potential indication of poor prognosis and advanced cancer clinical stage. However, the molecular mechanism of depression-associated poor prognoses of GC patients remains unclear. Recent studies have revealed that GC patients with depression are under high levels of oxidative stress (OS) status that is accompanied by the dysfunction of numerous proto-oncogenes, including the ABL proto-oncogene 1 (ABL1), which is a non-receptor tyrosine kinase. Recent evidence indicates that ABL1 was dysregulated in both major depressive disorder (MDD) and cancer patients with depression, and high levels of reactive oxygen species (ROS) can lead to the activation of ABL1 in response to OS and that activated ABL1 subsequently contributes to development of GC via interactions with the downstream targets and corresponding signaling pathways. In this review, we examine the evidence to illuminate the molecular mechanism of ABL1 in the progression of GC patients with depression and identify out new and effective methods for the initial and long-term treatment of GC.
Despite the decline in the morbidity of gastric cancer (GC) in recent years, GC remains the fourth most common cancer and the second-leading cause of cancer-related death globally with >700,000 human deaths per year (1,2). The occurrence of depression challenges cancer treatment and acts as an underlying indicator of advanced stages and poor prognoses of cancer patients (3). Depression care for cancer patients can improve the clinical benefit, including the treatment response (4,5). Nevertheless, there are currently no clear theories to explain the molecular mechanism by which depression is associated with poor prognoses among cancer patients. As an insult to the human body, depression causes oxidative stress (OS) (6), which subsequently leads to the excessive generation of reactive oxygen species (ROS) (7). Gastric tissues are particularly vulnerable to ROS (8). Excessive ROS that exceed the scavenging ability of human body trigger carcinogenesis by activating diverse proto-oncogenes, including ABL proto-oncogene 1 (ABL1) (9,10).
ABL1 is a non-receptor tyrosine kinase that consists of the N-terminal Src homology 3 (SH3) domain, Src homology 2 (SH2) domain, kinase domains, and the C-terminal actin-binding domain (ABD) (11). ABL1 was upregulated in GC and colorectal cancer patients with depression, and patients with major depressive disorder (MDD) (12,13). Activated ABL1 can regulate nuclear factor (erythroid-derived 2)-like 2 (NRF2) to function in an adaptive manner to react to OS (14). Additionally, activated ABL1 can consequently lead to dysfunctions of its downstream targets and corresponding signaling pathways, e.g., the mitogen-activated protein kinase (MAPK) and mechanistic target of rapamycin (mTOR), which contributes to the promotion of the development of GC and results in poor prognosis (14–17). Therefore, we will collect the evidence that ROS-activated ABL1 is responsible for the poor prognoses of GC patients with depression. Because inhibitors of ABL1, such as vandetanib, are widely used in clinical tumor treatment, clearly understanding the ABL1 in the process of GC will provide new methods to improve the prognoses of GC patients with depression.
2. Elevated levels of ROS are generated in GC patients with depression
Depression symptoms are common among GC patients both in Asia and the West (2,18–20). According to published reports, the prevalence of depression is ~50% among GC patients (2,21,22). The interaction of depression with cancer has long been a subject of investigation. The unambiguous mechanism responsible for the occurrence of depression among GC patients remains unknown. Inflammation is a crucial factor in gastric carcinogenesis (23). Due to inflammation, leukocytes release increased levels of cytokines and chemokines, e.g., TNF-α, IL-6, and chemokine (C-X-C motif) ligand 12 (CXCL12) (24–26). These cytokines and chemokines interact with the hypothalamic-pituitary-adrenal (HPA) axis, which may explain some of the mechanism of depression (27). Additionally, cancer diagnosis, post-diagnosis treatment, and cancer-related fatigue may also account for the occurrence of depression in GC (28). However, it is certain that depression is an indicator of poor prognosis among cancer patients, including patients with GC (4,29). In addition to other authors, we have suggested that depression is common among GC patients in our previous study (21). Compared with patients without depression, GC patients with depression exhibit shorter survival times. Furthermore, the prevalence of depression is positively correlated with the clinical stage of GC, i.e., GC patients with depression are susceptible to advanced stage cancer (22).
Emerging evidence suggests that OS works as primary crosslink between depression and GC. OS is primarily caused by the imbalance between oxidation and antioxidation in vivo. The recognized marker of OS 8-hydroxydeoxyguano-sine (8-OHdG) is positively correlated with Hospital Anxiety and Depression Scale (HADS)-D scores (30). Under OS, ROS levels are particularly raised among patients with depression. Decreased antioxidants and elevated oxidants enhance the generation of ROS in patients with depression. Clinical studies have revealed that depressive patients exhibit decreased levels of antioxidants, including glutathione peroxidase (GPX), catalase and superoxide dismutase (SOD), and these antioxidants exhibit ROS scavenging activities (31–33). Patients with depression also exhibit elevated levels of oxidants, such as nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and xanthine oxidase (XO), which leads to the production of ROS (34–37). Indeed, antidepressant treatment has been reported to reduce MDA (6). Our team discovered that 8-OHdG is significantly elevated in the sera of cancer patients, including GC patients, with depression compared with those without depression (13,21). All of the above changes could lead to the excessive generation of ROS (Fig. 1).
3. ROS generated in GC lead to the activation of ABL1
ABL1 is well known for its characteristics related to chronic myelogenous leukemia (CML) in the form of BCR-ABL1, which mediates abnormal myeloproliferation and leads to the development of CML (38). As a non-receptor tyrosine kinase, ABL1 is expressed in the cytoplasm and the nucleus and is involved in the processes of cell differentiation, proliferation, adhesion, and stress responses (39). Similar to other protein kinases, ABL1 is activated by a ligand and functions through interactions with downstream targets. Vitally, the expression of ABL1 is context-dependent and is upregulated in response to OS and DNA damage (10,14,40). In diverse cancers with OS that are accompanied by DNA damage, including CML, acute lymphoblastic leukemia (ALL), kidney, breast, ovarian and colorectal cancers, as well as GC, ABL1 is highly expressed (14,38,41–45). Thus, this system is a perfect model to probe the activation and the activities of ABL1 in fumarate hydratase-deficient kidney cancer. Fumarate hydratase deficiency results in the accumulation of fumarate, which subsequently leads to elevated NADPH oxidase levels and enhanced generation of ROS (10,14). ROS levels are positively associated with the expression of ABL1. Hydrogen peroxide, a type of ROS, promotes ABL1 expression, and the ROS scavenger N-acetylcysteine (NAC) could inhibit ABL1 expression. Therefore, the metabolic maladjustment-associated accumulation of ROS is the primary cause of the activation of ABL1. Indeed, in some types of cancer, ABL1 has been found to be associated with the level of ROS. ABL1 expression in these cancers is ROS-dependent. OS and excessive ROS generation are well-documented contributors to carcinogenesis in GC (33,46). In GC, ABL1 and c-Src tyrosine kinase (CSK) kinases phosphorylate cytotoxin-associated gene A (CagA), which is vital in the initial and development of gastric carcinogenesis (47). The activity of ABL1 is enhanced in the GTL-16 cell line (48). Therefore, the ROS generated in GC development might lead to the activation of ABL1. ROS can regulate the expression of ABL1; however, the potential mechanism is unknown.
The regulation of gene expression is a complex process, and only one report has discussed expression of ABL1 in GC as a target of miR-203. Epigenetically silenced miR-203 releases the expression of ABL1 to promote gastric lymphomagenesis (45). Furthermore, the increased expression of ABL1 by epigenetically silenced miR-203 has also been confirmed in CML (49,50). In Helicobacter pylori (Hp)-induced GC, miR-203 has been confirmed to be downregulated. Therefore, miR-203 may be a reason for the high level of ABL1 in GC. As mentioned above, the expression of ABL1 is ROS-dependent, and ROS can influence methylation status by sustaining the stability of hypoxia-inducible factor 1α (HIF-1α) (51), which increases the expression of the DNMT enzymes DNMT1 and DNMT3B, which keep gene silenced by hyper-methylation (52). Interestingly, HIF-1α can also result in the hypo-methylation of genes by regulating the MAT1A/MAT2A switch (53). Given the role of ROS in the epigenetic regulation of gene expression, the expression of ABL1 may be mediated by the ROS-related hyper-methylation of miR-203. Moreover, although the methylation of ABL1 in GC has not been clarified, in CML, dynamic methylation changes in the ABL1 promoter have been clearly identified (54,55). ROS might supervise the expression of ABL1 by directly influencing the methylation status of ABL1. Additionally, the activity of ABL1 can be triggered by receptor tyrosine kinases (RTKs), including epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), erb-b2 receptor tyrosine kinase 2 (ERBB2), vascular endothelial growth factor receptor (VEGFR), MET, c-ros oncogene 1, and receptor tyrosine kinase (ROS1), and their substrates (9,19,20). Importantly, EGFR, PDGFR, VEGFR, MET, and ROS1 have been proven to be elevated in GC (56–60). Moreover, some RTKs, such as EGFR, are regulated by ROS, and MET has been confirmed to interact with ABL1 (48,61). Therefore, ROS may affect the expression of ABL1 through a combination of a variety of mechanisms (Fig. 2). Additional studies should be designed to identify the detailed mechanism of the regulation of the expression of ABL1 by ROS in GC.
4. ABL1 contributes to cancer development in GC patients with depression
The function of ABL1 most strongly depends on its biological structure. As a tyrosine kinase, the N-terminal SH2 regulates the activation of kinase domains via contact with the SH2/N-lobe interface (62,63). The N-terminal SH3 is regulated by Ras and Rab interactor 1 (RIN1) and also influences the activation of ABL1 (64), and the kinase domain is involved its major activities. Based on its structure, ABL1 activates its substrates and associated signaling pathway to promote gastric tumorigenesis.
Both the expression and the activity of ABL1 are increased in GC (48,65). Our preliminary study confirmed that genes involved in DNA-damage signaling pathways were markedly dysregulation by gene chips in GC and colorectal carcinoma, including ABL1. ABL1 was significantly increased in GC patients with depression compared with that without depression (Table I, and unpublished data). Similarly, in colorectal carcinoma, we also concluded that ABL1 was significantly increased (Fig. 3) (13). Vitally, with whole-genome cRNA microarrays, Yi et al screened 30 differently expressed genes in patients with MDD, including ABL1 (12). In response to OS, ABL1 is the first to induce an adaptive pathway to protect the cell from ROS injury. ABL1 can upregulate nuclear respiratory factor 2 (NRF2), and NRF2 leads to high levels of antioxidant response elements (AREs), including NAD(P)H:quinone oxidoreductase 1 (NQO1) and aldo-keto reductase 1C1 (AKR1C1), which antagonize the DNA damage and the generation of ROS (66,67). Nevertheless, the function of NRF2 can be blocked by silent mating-type information regulation 2 homologue 1 (SIRT1), which is a gene that is related to MDD and influences the poor prognosis of GC (68–70). Thus, in GC patients with depression, the dysfunction of the protection system induced by SIRT1 may explain part of the mechanism responsible for the poor prognosis.
Secondly, GC cells exhibit features of the enduring activation of the Kirsten rat sarcoma viral oncogene homolog (K-ras)/extracellular signal-regulated kinase (ERK) signaling pathway (71). The ERK signaling pathway can directly induce the proliferation of cancer cell (72). Additionally, ERK also mediates the expression of miR-21, and increased in miR-21 decrease programmed cell death 4 (PDCD4) levels, which subsequently leads to anti-apoptosis and transformation effect on GC cells (73,74). Additionally, PTEN is also a target of miR-21, and decreased levels of PTEN account for the proliferation of GC cells (75). Indeed, studies have revealed that ABL1 can directly interact with RAS and activate the RAS/ERK signaling pathway to promote carcinogenesis of GC (76). Hence, ROS-dependent ABL1 triggers the RAS/ERK signaling pathway to promote the proliferation of GC cells directly or by affecting miR-21.
Third, in GC, hypoxia leads to the generation of ROS that prevent the degradation of HIF-1α (51). As a transcription factor, the accumulation of HIF-1α can modulate the expression of genes that are important in gastric tumorigenesis. For example, HIF-1α attenuates caveolin-1 (Cav-1) and leads to the epithelial-mesenchymal transition (EMT) in GC by regulating E-cadherin (77). HIF-1α activates the vascular endothelial growth factor (VEGF) pathway to enhance angiogenesis in GC (78). Crosstalk between HIF-1α and the tumor suppressor gene p53 has also been discovered, and the expressions of both of these factors are correlated with ROS (79,80). HIF-1α also induces miR-328 to inhibit the activity of PTEN, which then releases the suppression of the mTOR signaling pathway to promote GC cell survival (81). Notably, ROS-dependent ABL1 directly communicates with p53 in the GC cell line GTL-16 to promote gastric tumorigenesis (48). Moreover, there is also evidence that ABL1 can enhance the activity of HIF-1α via the mTOR signaling pathway (14). Therefore, ABL1 participates in parts of the mechanism of gastric carcinogenesis by affecting HIF-1α.
Finally, as discussed above, ABL1 can be activated by RTK, and RTK can be activated and act as a substrate of ABL1. One thoroughly investigated factor in GC is CSK (82). Humar et al found that CSK was activated in mesenchyme-like cancer cells and that CSK activation is a central event that is required for the development of early diffuse GC. More importantly, the activation of CSK is mediated by ABL1 via the activation of the Src homology 2 domain-containing 1 (SHC1) of CSK (15). Phosphatidylinositol 3-kinase (PI3K) is also a substrate of ABL1, and the induction of PI3K can trigger the PI3K/v-akt murine thymoma viral oncogene homolog 1 (AKt)/mTOR signaling pathway, which can result in the development of GC (1,15).
For GC patients, excessive ROS are produced due to low levels of antioxidants and high levels of oxidants (83). Moreover, the occurrence of depression among GC patients enhances the production of ROS via a similar mechanism (13,84). ROS act to directly increase the expression of ABL1 (9,14,85). Additionally, ROS also trigger tyrosine kinase inhibitor (TKI) to increase the activity of ABL1 (34,61). Importantly, in Hp infection-associated GC, ABL1 functions as a proto-oncogene by phosphorylating CagA to promote tumorigenesis (47,86). Taken together, these findings indicate that ABL1 contributes to the protection of cells from ROS by inducing NRF2 and enhancing the activity of HIF-1α to catalyze its substrate and corresponding substrates to promote carcinogenesis of GC patients with depression (Fig. 4).
5. Conclusions
ABL1 regulates cell proliferation in Hp-induced gastric B-cell lymphomas in mucosa-associated lymphoid tissue (MALT) lymphoma, and blocking the activity of ABL1 with imatinib can inhibit cell proliferation (45). GTL16 is a subclone of MKN45 that is characterized as 'Met-addicted' (87). In GTL16, ABL1 has been proven to be activated by Met, and the activation of ABL1 then mediates the phosphorylation of p53 by p38-MAPKs, which results in the overexpression of MDM2, which in turn promotes cell proliferation. Similarly, the effect of ABL1 in GTL16 can be interfered with by imatinib and shRNA interference (48). As discussed above, GC patients with depression have high levels of ROS, and ABL1 may be directly regulated by ROS-related methylation or miR-203, or the ROS-activated ligands of ABL1 may act to indirectly promote the activation of ABL1. Therefore, treatments with TKIs may be clinically beneficial for GC patients with depression.
6. Perspective
Collectively, considering the above clinical results, depression is a world-class problem and is frequent among cancer patients. Depression in GC patients is associated with shorter survival times. Worse, there are no ideal drugs for clinical depression. Therefore, the probing of the underlying molecular changes associated with depression in cancer patients represents a new option. We focus our studies on the role of OS and its product ROS in GC and depression and conclude that ROS serve as a crosslink for both; i.e., ROS mediate a mutual promotion process for depression and GC. In this review, we elucidated the molecular mechanism of the poor prognosis of GC patients with depression and found that ABL1, which is a non-receptor tyrosine kinase, may function as a crucial factor in the development of GC and the poor prognoses of GC patients with depression. High ROS levels in GC patients lead to the activation of ABL1, and ABL1 then induces NRF2 to protect the cells from ROS injury. ABL1 results in tumorigenesis in GC by phosphorylating its substrates and activating signaling pathways. Considering that inhibitors of ABL1 have been widely used in the treatment of CML, it is possible to assess the value of ABL1 in the treatment of GC patients with depression.
However, because ABL1 is widely expressed in the human body and is required for the maintenance of normal physiological functions, e.g., tissue development and immune function, it is difficult to avoid the side-effects of ABL1 inhibitors that are related to these physiological functions. Furthermore, the activity of ABL1 is tissue-specific and context-dependent; thus, future explorations of ABL1 should primarily concentrate on research into the biological processes in which ABL1 functions rather than employing old gene-centric styles. Nevertheless, probing the mediation of the ABL1-dependent phosphorylation of GC should elucidate some of the reasons for GC-related cell death. Given the accumulated evidence, the FDA-approved status of TKIs, and the experience of patients with other cancers, including CML, AML, lung and breast cancer, following exposure to these drugs, ABL represents a prospective target for future treatments for GC patients with depression.
Acknowledgments
This project was supported by the Natural Science Foundation of Shaanxi Province (no. 99SM50), the National Natural Science Foundation of China (nos. 81171288 and 81673033) for the research of OS and depression, and the Fundamental Research Funds for the Central Universities (no. 0601-08143036).
ReferencesRiquelmeISaavedraKEspinozaJAWeberHGarcíaPNerviBGarridoMCorvalánAHRoaJCBizamaCMolecular classification of gastric cancer: Towards a pathway-driven targeted therapy62475024779201510.18632/oncotarget.4990262673244694793HongJSTianJPrevalence of anxiety and depression and their risk factors in Chinese cancer patients22453459201410.1007/s00520-013-1997-yDelgado-GuayMFerrerJRieberAGRhondaliWTayjasanantSOchoaJCantuHChisholmGWilliamsJFrisbee-HumeSFinancial distress and its associations with physical and emotional symptoms and quality of life among advanced cancer patients2010921098201510.1634/theoncologist.2015-0026262057384571810WalkerJHansenCHMartinPSymeonidesSGourleyCWallLWellerDMurrayGSharpeMSMaRT (Symptom Management Research Trials) Oncology-3 TeamIntegrated collaborative care for major depression comorbid with a poor prognosis cancer (SMaRT Oncology-3): A multicentre randomised controlled trial in patients with lung cancer1511681176201410.1016/S1470-2045(14)70343-225175097AndersenBLDeRubeisRJBermanBSGrumanJChampionVLMassieMJHollandJCPartridgeAHBakKSomerfieldMRAmerican Society of Clinical OncologyScreening, assessment, and care of anxiety and depressive symptoms in adults with cancer: An American Society of Clinical Oncology guideline adaptation3216051619201410.1200/JCO.2013.52.4611247337934090422Jiménez-FernándezSGurpeguiMDíaz-AtienzaFPérez-CostillasLGerstenbergMCorrellCUOxidative stress and antioxidant parameters in patients with major depressive disorder compared to healthy controls before and after antidepressant treatment: Results from a meta-analysis7616581667201510.4088/JCP.14r0917926579881Hermes-LimaMMoreiraDCRivera-IngrahamGAGiraud-BilloudMGenaro-MattosTCCamposEGPreparation for oxidative stress under hypoxia and metabolic depression: Revisiting the proposal two decades later8911221143201510.1016/j.freeradbiomed.2015.07.15626408245ChaturvediRde SabletTAsimMPiazueloMBBarryDPVerriereTGSierraJCHardbowerDMDelgadoAGSchneiderBGIncreased Helicobacter pylori-associated gastric cancer risk in the Andean region of Colombia is mediated by spermine oxidase3434293440201510.1038/onc.2014.2734345146WarschWGrundschoberEBergerAGilleLCerny-ReitererSTiganASHoelbl-KovacicAValentPMorigglRSexlVSTAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia316691687201210.18632/oncotarget.806No authors listedFH-deficient cancers depend on ABL1-mediated metabolic adaptation5OF9201510.1158/2159-8290.CD-RW2014-257WangJYThe capable ABL: What is its biological function?3411881197201410.1128/MCB.01454-13244213903993570YiZLiZYuSYuanCHongWWangZCuiJShiTFangYBlood-based gene expression profiles models for classification of subsyndromal symptomatic depression and major depressive disorder7e31283201210.1371/journal.pone.0031283223480663278427WeiYCZhouFLHeDLBaiJRHuiLYWangXYNanKJThe level of oxidative stress and the expression of genes involved in DNA-damage signaling pathways in depressive patients with colorectal carcinoma66259266200910.1016/j.jpsychores.2008.09.00119232240SourbierCRickettsCJMatsumotoSCrooksDRLiaoPJMannesPZYangYWeiMHSrivastavaGGhoshSTargeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer26840850201410.1016/j.ccell.2014.10.005254904484386283KolchWPittAFunctional proteomics to dissect tyrosine kinase signalling pathways in cancer10618629201010.1038/nrc290020720570LvBSongCWuLZhangQHouDChenPYuSWangZChuYZhangJNetrin-4 as a biomarker promotes cell proliferation and invasion in gastric cancer697949806201510.18632/oncotarget.3400259091664496398DemitrackESGiffordGBKeeleyTMCarulliAJVanDussenKLThomasDGiordanoTJLiuZKopanRSamuelsonLCNotch signaling regulates gastric antral LGR5 stem cell function3425222536201510.15252/embj.201490583262711034609184TavoliAMohagheghiMAMontazeriARoshanRTavoliZOmidvariSAnxiety and depression in patients with gastrointestinal cancer: Does knowledge of cancer diagnosis matter?728200710.1186/1471-230X-7-28176299281971049ShiMLiuDDuanHHanCWeiBQianLChenCGuoLHuMYuMCatecholamine up-regulates MMP-7 expression by activating AP-1 and STAT3 in gastric cancer92692010209398932964618AudierAGDetermination of a constitutional neuroendocrine factor probably influencing tumor development in man: Prophylactic and therapeutic aspects1120320819883292042WeiYCZhouFLHeDLBaiJRDingHWangXYNanKJOxidative stress in depressive patients with gastric adenocarcinoma1210891096200910.1017/S146114570900009119272208NordinKBerglundGGlimeliusBSjödénPOPredicting anxiety and depression among cancer patients: A clinical model37376384200110.1016/S0959-8049(00)00398-111239760HayakawaYAriyamaHStancikovaJSakitaniKAsfahaSRenzBWDubeykovskayaZAShibataWWangHWestphalenCBMist1 expressing gastric stem cells maintain the normal and neoplastic gastric epithelium and are supported by a perivascular stem cell niche28800814201510.1016/j.ccell.2015.10.003265854004684751LimKHyunYMLambert-EmoKCapeceTBaeSMillerRTophamDJKimMNeutrophil trails guide influenza-specific CD8+ T cells in the airways349aaa4352201510.1126/science.aaa4352FinisguerraVDi ConzaGDi MatteoMSerneelsJCostaSThompsonAAWautersEWalmsleySPrenenHGranotZMET is required for the recruitment of anti-tumoural neutrophils522349353201510.1038/nature14407259851804594765HarkerJALewisGMMackLZunigaEILate interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection334825829201110.1126/science.1208421219605303388900HodesGEKanaVMenardCMeradMRussoSJNeuroimmune mechanisms of depression1813861393201510.1038/nn.4113264047134843114ShiQSmithTGMichonskiJDSteinKDKawCCleelandCSSymptom burden in cancer survivors 1 year after diagnosis: A report from the American Cancer Society's Studies of Cancer Survivors11727792790201110.1002/cncr.26146214950263143572SoubeyranPFonckMBlanc-BissonCBlancJFCeccaldiJMertensCImbertYCanyLVogtLDaubaJPredictors of early death risk in older patients treated with first-line chemotherapy for cancer3018291834201210.1200/JCO.2011.35.744222508806LiuZZhangJYanJWangYLiYLeucocyte telomere shortening in relation to newly diagnosed type 2 diabetic patients with depression2014673959201410.1155/2014/673959248683164020220RybkaJKędziora-KornatowskaKBanaś-LeżańskaPMajsterekICarvalhoLACattaneoAAnackerCKędzioraJInterplay between the pro-oxidant and antioxidant systems and proinflammatory cytokine levels, in relation to iron metabolism and the erythron in depression63187194201310.1016/j.freeradbiomed.2013.05.01923707456YangSLYuPLChungKRThe glutathione peroxidase-mediated reactive oxygen species resistance, fungicide sensitivity and cell wall construction in the citrus fungal pathogen Alternaria alternata18923935201610.1111/1462-2920.13125BhattacharyyaAChattopadhyayRMitraSCroweSEOxidative stress: An essential factor in the pathogenesis of gastrointestinal mucosal diseases94329354201410.1152/physrev.00040.2012246923504044300ChanECJiangFPeshavariyaHMDustingGJRegulation of cell proliferation by NADPH oxidase-mediated signaling: Potential roles in tissue repair, regenerative medicine and tissue engineering12297108200910.1016/j.pharmthera.2009.02.00519285105WangHMaLLiYChoCHExposure to cigarette smoke increases apoptosis in the rat gastric mucosa through a reactive oxygen species-mediated and p53-independent pathway2811251131200010.1016/S0891-5849(00)00207-010832074SeoJSParkJYChoiJKimTKShinJHLeeJKHanPLNADPH oxidase mediates depressive behavior induced by chronic stress in mice3296909699201210.1523/JNEUROSCI.0794-12.201222787054MaesMGaleckiPChangYSBerkMA review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness35676692201110.1016/j.pnpbp.2010.05.004HolmFHellqvistEMasonCNAliSADelos-SantosNBarrettCLChunHJMindenMDMooreRAMarraMAReversion to an embryonic alternative splicing program enhances leukemia stem cell self-renewal1121544415449201510.1073/pnas.1506943112266217264687548ColicelliJABL tyrosine kinases: Evolution of function, regulation, and specificity3re6201010.1126/scisignal.3139re6208415682954126De KeersmaeckerKRocnikJLBernadRLeeBHLeemanDGielenOVerachtertHFolensCMunckSMarynenPKinase activation and transformation by NUP214-ABL1 is dependent on the context of the nuclear pore31134142200810.1016/j.molcel.2008.05.00518614052JabbourEKantarjianHRavandiFThomasDHuangXFaderlSPemmarajuNDaverNGarcia-ManeroGSasakiKCombination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: A single-centre, phase 2 study1615471555201510.1016/S1470-2045(15)00207-7264320464816046GreuberEKSmith-PearsonPWangJPendergastAMRole of ABL family kinases in cancer: From leukaemia to solid tumours13559571201310.1038/nrc3563238426463935732DebSWongSQLiJDoHWeissJByrneDChakrabartiABosmaTFellowesADobrovicAkConFab InvestigatorsMutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations11123512360201410.1038/bjc.2014.511254906784264438CunninghamJMVierkantRASellersTAPhelanCRiderDNLiebowMSchildkrautJBerchuckACouchFJWangXOvarian Cancer Association ConsortiumCell cycle genes and ovarian cancer susceptibility: A tagSNP analysis10114611468200910.1038/sj.bjc.6605284197386112768434CraigVJCogliattiSBRehrauerHWündischTMüllerAEpigenetic silencing of microRNA-203 dysregulates ABL1 expression and drives Helicobacter-associated gastric lymphomagenesis7136163624201110.1158/0008-5472.CAN-10-390721454413ChiangYTYenYWLoCLReactive oxygen species and glutathione dual redox-responsive micelles for selective cytotoxicity of cancer61150161201510.1016/j.biomaterials.2015.05.00726002788MüllerAMultistep activation of the Helicobacter pylori effector CagA12211921195201210.1172/JCI61578223780393314475FurlanAStagniVHussainARichelmeSContiFProdosmoADestroARoncalliMBarilàDMainaFAbl interconnects oncogenic Met and p53 core pathways in cancer cells1816081616201110.1038/cdd.2011.23214552203172114BuenoMJPérez de CastroIGómez de CedrónMSantosJCalinGACigudosaJCCroceCMFernández-PiquerasJMalumbresMGenetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression13496506200810.1016/j.ccr.2008.04.01818538733FaberJGregoryRIArmstrongSALinking miRNA regulation to BCR-ABL expression: The next dimension13467469200810.1016/j.ccr.2008.05.01318538729ParkJHKimTYJongHSKimTYChunYSParkJWLeeCTJungHCKimNKBangYJGastric epithelial reactive oxygen species prevent normoxic degradation of hypoxia-inducible factor-1alpha in gastric cancer cells9433440200312538497WatsonCJCollierPTeaINearyRWatsonJARobinsonCPhelanDLedwidgeMTMcDonaldKMMcCannAHypoxia-induced epigenetic modifications are associated with cardiac tissue fibrosis and the development of a myofibroblast-like phenotype2321762188201410.1093/hmg/ddt614FrauMFeoFPascaleRMPleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis59830841201310.1016/j.jhep.2013.04.03123665184AsimakopoulosFAShteperPJKrichevskySFibachEPolliackARachmilewitzEBen-NeriahYBen-YehudaDABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia9424522460199910498618SunBJiangGZaydanMALa RussaVFSafahHEhrlichMABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors6169316937200111559572HayashiYBardsleyMRToyomasuYMilosavljevicSGajdosGBChoiKMReid-LombardoKMKendrickMLBingener-CaseyJTangCMPlatelet-derived growth factor receptor-α regulates proliferation of gastrointestinal stromal tumor cells with mutations in KIT by stabilizing ETV114942032.e16201510.1053/j.gastro.2015.04.006WuZZhangZGeXLinYDaiCChangJLiuXGengRWangCChenHIdentification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer640519405342015265287574747350JavleMSmythECChauIRamucirumab: Successfully targeting angiogenesis in gastric cancer2058755881201410.1158/1078-0432.CCR-14-1071252816954252869KubokiYYamashitaSNiwaTUshijimaTNagatsumaAKuwataTYoshinoTDoiTOchiaiAOhtsuAComprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer27127133201610.1093/annonc/mdv508LeeJLeeSEKangSYDoIGLeeSHaSYChoJKangWKJangJOuSHIdentification of ROS1 rearrangement in gastric adenocarcinoma11916271635201310.1002/cncr.2796723400546HöckerMRosenbergIXavierRHenihanRJWiedenmannBRosewiczSPodolskyDKWangTCOxidative stress activates the human histidine decarboxylase promoter in AGS gastric cancer cells2732304623054199810.1074/jbc.273.36.230469722530LorenzSDengPHantschelOSuperti-FurgaGKuriyanJCrystal structure of an SH2-kinase construct of c-Abl and effect of the SH2 domain on kinase activity468283291201510.1042/BJ2014149225779001DölkerNGórnaMWSuttoLTorralbaASSuperti-FurgaGGervasioFLThe SH2 domain regulates c-Abl kinase activation by a cyclin-like mechanism and remodulation of the hinge motion10e1003863201410.1371/journal.pcbi.1003863252993464191882ThaiMTingPYMcLaughlinJChengDMüschenMWitteONColicelliJABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN125290300201110.1038/leu.2010.2683049868ChungKSHanGKimBKKimHMYangJSAhnJLeeKSongKBWonMA novel antitumor piperazine alkyl compound causes apoptosis by inducing RhoB expression via ROS mediated c Abl/p38 MAPK signaling7213151324201310.1007/s00280-013-2310-y24121479ChenCCChuCBLiuKJHuangCYChangJYPanWYChenHHChengYHLeeKDChenMFGene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: The role of IL-6 signaling and Nrf2/AKR1C axis identification86872887201310.1016/j.bcp.2013.07.02523933386Ramos-GomezMKwakMKDolanPMItohKYamamotoMTalalayPKenslerTWSensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice9834103415200110.1073/pnas.0516187981124809230667CaiNBigdeliTBKretzschmarWLiYLiangJSongLHuJLiQJinWHuZCONVERGE consortiumSparse whole-genome sequencing identifies two loci for major depressive disorder523588591201510.1038/nature14659NabaviSFBilottoSRussoGLOrhanIEHabtemariamSDagliaMDeviKPLoizzoMRTundisRNabaviSMOmega-3 polyunsaturated fatty acids and cancer: Lessons learned from clinical trials34359380201510.1007/s10555-015-9572-226227583ChaEJNohSJKwonKSKimCYParkBHParkHSLeeHChungMJKangMJLeeDGExpression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma1544534459200910.1158/1078-0432.CCR-08-332919509139XingRLiWCuiJZhangJKangBWangYWangZLiuSLuYGastrokine 1 induces senescence through p16/Rb pathway activation in gastric cancer cells614352201210.1136/gut.2010.230623LetoSMSassiFCatalanoITorriVMigliardiGZanellaERThrosbyMBertottiATrusolinoLSustained inhibition of HER3 and EGFR is necessary to induce regression of HER2-amplified gastrointestinal carcinomas2155195531201510.1158/1078-0432.CCR-14-306626296355TuHSunHLinYDingJNanKLiZShenQWeiYOxidative stress upregulates PDCD4 expression in patients with gastric cancer via miR-212019171923201410.2174/13816128113199990547LingMLiYXuYPangYShenLJiangRZhaoYYangXZhangJZhouJRegulation of miRNA-21 by reactive oxygen species-activated ERK/NF-κB in arsenite-induced cell transformation5215081518201210.1016/j.freeradbiomed.2012.02.02022387281ShiZZhangJQianXHanLZhangKChenLLiuJRenYYangMZhangAAC1MMYR2, an inhibitor of dicer-mediated biogenesis of Oncomir miR-21, reverses epithelial-mesenchymal transition and suppresses tumor growth and progression7355195531201310.1158/0008-5472.CAN-13-028023811941AlbanoFZagariaAAnelliLCoccaroNImperaLMinerviniCFMinerviniARossiARTotaGCasieriPGene expression profiling of chronic myeloid leukemia with variant t(9;22) reveals a different signature from cases with classic translocation1236201310.1186/1476-4598-12-36236420273658885KannanAKrishnanAAliMSubramaniamSHalagowderDSivasithamparamNDCaveolin-1 promotes gastric cancer progression by up-regulating epithelial to mesenchymal transition by crosstalk of signalling mechanisms under hypoxic condition50204215201410.1016/j.ejca.2013.08.016RathSDasLKokateSBPratheekBMChattopadhyaySGoswamiCChattopadhyayRCroweSEBhattacharyyaARegulation of Noxa-mediated apoptosis in Helicobacter pylori-infected gastric epithelial cells29796806201510.1096/fj.14-257501SumiyoshiYKakejiYEgashiraAMizokamiKOritaHMaeharaYOverexpression of hypoxia-inducible factor 1alpha and p53 is a marker for an unfavorable prognosis in gastric cancer1251125117200610.1158/1078-0432.CCR-05-238216951228HammondEMGiacciaAJHypoxia-inducible factor-1 and p53: Friends, acquaintances, or strangers?1250075009200610.1158/1078-0432.CCR-06-061316951213SeokJKLeeSHKimMJLeeYMMicroRNA-382 induced by HIF-1α is an angiogenic miR targeting the tumor suppressor phosphatase and tensin homolog4280628072201410.1093/nar/gku515249140514081109HumarBFukuzawaRBlairVDunbierAMoreHCharltonAYangHKKimWHReeveAEMartinIDestabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer6724802489200710.1158/0008-5472.CAN-06-302117363565BauerGBereswillSAichelePGlockerEHelicobacter pylori protects oncogenically transformed cells from reactive oxygen species-mediated intercellular induction of apoptosis3515821591201410.1093/carcin/bgu07424662971Mendes-da-SilvaRFLopes-de-MoraisAABandim-da-SilvaMECavalcantiGARodriguesARAndrade-da-CostaBLGuedesRCProoxidant versus antioxidant brain action of ascorbic acid in well-nourished and malnourished rats as a function of dose: A cortical spreading depression and malondialdehyde analysis86155160201410.1016/j.neuropharm.2014.06.02725008558Bolton-GillespieESchemionekMKleinHUFlisSHoserGLangeTNieborowska-SkorskaMMaierJKerstiensLKoptyraMGenomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells12141754183201310.1182/blood-2012-11-466938235434573656452WeiJO'BrienDVilgelmAPiazueloMBCorreaPWashingtonMKEl-RifaiWPeekRMZaikaAInteraction of Helicobacter pylori with gastric epithelial cells is mediated by the p53 protein family13414121423200810.1053/j.gastro.2008.01.072183433782430883BertottiABraccoCGirolamiFTortiDGastaldiSGalimiFMedicoEElvinPComoglioPMTrusolinoLInhibition of Src impairs the growth of met-addicted gastric tumors1639333943201010.1158/1078-0432.CCR-10-010620628031
High levels of ROS in GC patients with depression. Decreased levels of antioxidants, including GPX, catalase and SOD, cooperate with increased levels of oxidants, including NADPH oxidase and XO, to promote the generation of ROS in GC patients with depression. ROS, reactive oxygen species; GC, gastric cancer; GPX, glutathione peroxidase; SOD, superoxide dismutase; NADPH, nicotinamide adenine dinucleotide phosphate; XO, xanthine oxidase.
Expression and activation of ABL1 in GC. miR-203 and methylation can regulate the expression of ABL1 at the gene level. RTKs, including EGFR, PDGFR, VEGFR, MET, and ROS1 can activate ABL1. ABL1, ABL proto-oncogene 1; GC, gastric cancer; RTKs, receptor tyrosine kinases; EGFR, epidermal growth factor receptor; PDGFR, platelet-derived growth factor receptor; VEGFR, vascular endothelial growth factor receptor.
ABL1 was significantly increased in colorectal carcinoma patients with depression. ABL1, ABL proto-oncogene 1.
The ABL1-related signaling pathway in cancer development in GC patients with depression. High levels of ROS in GC patients with depression lead to the activation of ABL1, and ABL1 then induces NRF2 to protect cell from ROS injury. ABL1 results in tumorigenesis in GC by phosphorylating its substrates PI3K, Ras, and CSK and the associated signaling pathways. ABL1, ABL proto-oncogene 1; GC, gastric cancer; ROS, reactive oxygen species; NRF2, nuclear factor (erythroid-derived 2)-like 2; PI3K, phosphatidylinositol 3-kinase; CSK, c-Src tyrosine kinase.
Different expressions of genes involved in DNA-damage signaling pathways in GC patients without and with depression.
Symbol
Gene name
2−ΔΔCt
Relative expression
Group A
Group B
Group A/group B
ABL1
ABL/JTK7
4.50E-04
7.20E-05
6.32
APEX1
APE/APE1
4.10E-01
1.50E-01
2.69
ATM
AT1/ATA
9.00E-03
1.20E-02
−1.29
ATR
FRP1/MEC1
6.30E-03
1.20E-02
−1.95
ATRX
ATR2/MRXS3
1.50E-02
2.00E-02
−1.3
BRCA1
BRCAI/BRCC1
2.00E-03
1.50E-03
1.34
BTG2
PC3/TIS21
9.20E-03
4.20E-03
2.16
CCNH
CAK/p34
2.10E-04
5.00E-04
−2.35
CDK7
CAK1/CDKN7
1.20E-02
7.80E-03
1.51
CHEK1
CHK1
3.80E-02
2.40E-02
1.6
CHEK2
CDS1/CHK2
1.50E-02
8.10E-03
1.8
CIB1
CALMYRIN/CIB
3.00E-01
4.20E-01
−1.42
CIDEA
CIDE-A
1.10E-04
4.90E-05
2.31
CRY1
PHLL1
3.70E-02
2.10E-02
1.77
DDB1
DDBA/UV-DDB1
1.20E-01
8.00E-02
1.54
DDIT3
CEBPZ/CHOP
3.20E-02
1.10E-01
−3.34
DMC1
DMC1H/HsLim15
3.70E-04
8.10E-04
−2.17
ERCC1
UV20
5.60E-02
6.30E-02
−1.13
ERCC2
EM9/XPD
1.90E-02
3.10E-02
−1.62
EXO1
HEX1/hExoI
2.10E-02
1.30E-02
1.68
FANCG
FAG/XRCC9
2.40E-02
2.00E-02
1.23
FEN1
FEN-1/MF1
3.60E-02
1.00E-02
3.58
XRCC6
CTC75/CTCBF
2.40E-01
2.30E-01
1.06
GADD45A
DDIT1/GADD45
6.80E-03
1.30E-02
−1.91
GADD45G
CR6/DDIT2
4.60E-03
2.20E-02
−4.82
GML
LY6DL
3.10E-05
4.90E-05
−1.56
GTF2H1
BTF2/TFIIH
3.50E-02
2.00E-02
1.82
GTF2H2
BTF2/BTF2P44
8.50E-03
2.00E-02
−2.3
GTSE1
B99
3.80E-02
7.50E-02
−1.99
HUS1
Hus1
3.50E-02
4.80E-02
−1.38
IGHMBP2
CATF1/HCSA
1.20E-02
3.30E-02
−2.75
IHPK3
INSP6K3/IP6K3
6.10E-05
5.70E-03
−93.05
XRCC6BP1
KUB3
2.50E-02
1.10E-02
2.25
LIG1
MGC117397
2.30E-02
6.20E-02
−2.69
MAP2K6
MAPKK6/MEK6
1.00E-02
3.30E-03
3.12
MAPK12
ERK3/ERK6
3.00E-03
2.50E-03
1.19
MBD4
MED1
6.20E-02
9.40E-02
−1.53
MLH1
COCA2/FCC2
1.80E-02
1.10E-02
1.74
MLH3
HNPCC/HNPCC7
3.60E-02
4.70E-02
−1.31
MNAT1
MAT1/RNF66
1.10E-02
1.70E-02
−1.57
MPG
AAG/APNG
1.50E-01
1.50E-01
−1
MRE11A
ATLD/HNGS1
2.50E-02
4.50E-02
−1.78
MSH2
COCA1/FCC1
2.10E-02
1.40E-02
1.49
MSH3
MSH3
8.60E-03
1.70E-02
−2.03
MUTYH
MYH/MYHβ
7.70E-02
1.90E-01
−2.46
N4BP2
B3BP
2.40E-03
5.30E-03
−2.17
NBN
AT-V1/AT-V2
6.70E-02
2.00E-02
3.43
NTHL1
NTH1/OCTS3
5.10E-02
1.30E-01
−2.48
OGG1
HMMH/HOGG1
3.40E-02
3.00E-02
1.15
PCBP4
LIP4/MCG10
2.60E-04
2.30E-03
−8.69
PCNA
MGC8367
6.10E-01
1.30E-01
4.82
PDCD8
AIF
6.70E-02
1.10E-01
−1.64
PMS1
DKFZp781M0253/HNPCC3
1.60E-02
2.10E-02
−1.27
PMS2
HNPCC4/PMS2CL
2.50E-02
4.50E-02
−1.78
PMS2L3
PMS2L9/PMS5
1.30E-02
4.40E-02
−3.39
PNKP
PNK
3.00E-02
6.30E-02
−2.13
PPP1R15A
GADD34
4.70E-03
5.50E-03
−1.17
PRKDC
DNAPK/DNPK1
2.70E-02
3.60E-02
−1.31
RAD1
HRAD1/REC1
8.60E-03
1.10E-02
−1.26
RAD17
CCYC/HRAD17
1.90E-02
3.90E-02
−2.07
RAD18
RNF73
7.90E-03
1.20E-02
−1.48
RAD21
HR21/HRAD21
5.10E-01
9.50E-02
5.31
RAD50
RAD50-2/hRad50
1.20E-02
1.00E-02
1.14
RAD51
BRCC5/HRAD51
7.70E-03
1.90E-03
4.03
RAD51L1
R51H2/RAD51B
1.90E-03
2.90E-03
−1.53
RAD9A
RAD9
9.40E-06
4.90E-05
−5.21
RBBP8
CTIP/RIM
7.80E-02
5.70E-02
1.38
REV1L
REV1
2.00E-02
4.40E-02
−2.2
RPA1
HSSB/REPA1
4.00E-02
3.90E-02
1.02
SEMA4A
SEMAB/SEMB
2.10E-03
1.50E-03
1.37
SESN1
PA26/SEST1
7.40E-02
1.00E-02
7.36
SMC1L1
DKFZp686L19178/DXS423E
6.00E-02
8.30E-02
−1.38
SUMO1
GMP1/PIC1
2.70E-01
2.60E-01
1.05
TP53
LFS1/TRP53
2.80E-02
1.20E-02
2.39
TP73
P73
1.30E-03
3.50E-03
−2.81
TREX1
ATRIP/DKFZp434J0310
4.70E-03
8.90E-03
−1.91
UNG
DGU/DKFZp781L1143
3.20E-02
1.00E-02
3.12
XPA
XP1/XPAC
9.50E-02
4.50E-02
2.1
XPC
XP3/XPCC
1.10E-02
3.00E-02
−2.68
XRCC1
RCC
2.80E-02
5.90E-02
−2.07
XRCC2
DKFZp781P0919
7.30E-03
3.60E-03
2.04
XRCC3
XRCC3
1.70E-02
1.00E-02
1.62
ZAK
AZK/MLK7
3.60E-02
2.40E-02
1.52
Group A represents GC patients with depression; group B represents GC patients without depression. GC, gastric cancer; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase.